Home
News
Screeners
Insights
Rekvina Laboratories
30.
68
+1.46
(+5.00%)
Market Cap
₹18.48 Cr
PE Ratio
-69.57
Industry
Healthcare
Buy
Sell
Company Performance:
1D
+5.00%
1M
-14.78%
6M
+57.58%
1Y
+333.33%
5Y
+707.37%
View Company Insights
Latest news about Rekvina Laboratories
Rekvina Labs acquirers consolidate 64.30% stake after open offer
9 days ago
Rekvina Laboratories Limited acquirers Surbhit Mukesh Shah, Amit Mukesh Shah, and Dhruvalkumar Patel have consolidated a 64.30% stake after accepting all tendered shares in their open offer. The partial subscription leaves a 23% public float, with the promoter group's stake expected to rise to 77.00% following the SEPA transaction.
Rekvina Labs open offer at ₹10 per share opens July 1
Jun 30, 2026
Rekvina FY26 Net Loss ₹25.47 Lacs, Revenue ₹126.54 Lacs
May 22, 2026
Rekvina Laboratories Discloses Voting Results for EGM on Capital Restructuring
Apr 11, 2026
Rekvina Laboratories Claims Exemption from Annual Secretarial Compliance Report for FY26
Apr 07, 2026
More news about Rekvina Laboratories
06
Apr 26
Rekvina Laboratories Submits Q4FY26 Dematerialisation Compliance Certificate to BSE
Rekvina Laboratories Limited filed its Q4FY26 dematerialisation compliance certificate with BSE on 06.04.2026, covering the period from 1st January, 2026 to 31st March, 2026. The certificate, prepared by registrar M/s. Purva Sharegistry India Pvt. Ltd, shows no dematerialisation activity during the quarter, with 'NIL' entries across all parameters including folio numbers, shareholder names, and certificate numbers. This regulatory filing under SEBI (Depositories and Participants) Regulations, 2018 ensures compliance with quarterly reporting requirements for listed companies.
25
Mar 26
Rekvina Laboratories Open Offer: Detailed Public Statement Published for 26% Stake Acquisition
Three acquirers have published a detailed public statement for their mandatory open offer to acquire 28,90,100 equity shares (26% stake) of Rekvina Laboratories at ₹10 per share, following a share swap agreement to acquire Radiant Parenterals. The offer involves ₹2,89,01,000 consideration with escrow arrangements in place and is scheduled to run from May 14-27, 2026.
18
Mar 26
Rekvina Laboratories Schedules EGM for April 10 to Approve Capital Restructuring
Rekvina Laboratories has formally notified shareholders of an extraordinary general meeting on April 10, 2026, to vote on increasing authorized share capital from ₹3.50 crore to ₹6 crore, acquiring 100% stake in Radiant Parenterals for ₹4.62 crore through share exchange, and issuing additional equity shares for cash consideration.
17
Mar 26
Rekvina Laboratories Discloses Open Offer Public Announcement to BSE
Rekvina Laboratories Limited has formally disclosed to BSE Limited the receipt of a public announcement for an open offer by three acquirers - Surbhit Mukesh Shah, Amit Mukesh Shah, and Dhruvalkumar Patel. The offer seeks to acquire 28,90,100 equity shares at ₹10 per share, representing 26% of expanded share capital with total consideration of ₹2,89,01,000. The transaction was triggered by a share exchange agreement for acquiring Radiant Parenterals Limited, managed by Vivro Financial Services under SEBI regulations.
Rekvina Laboratories
30.
68
+
1.
46
(+
5.
00
%)
1 Year Returns:
+333.33%
Industry Peers
Sun Pharmaceutical
1,944.40
(-
0.
03
%)
Divis Laboratories
8,300.00
(+
0.
30
%)
Torrent Pharmaceuticals
4,924.00
(0.0%)
Cipla
1,467.70
(+
0.
27
%)
Zydus Life Science
1,119.00
(+
0.
43
%)
Lupin
2,300.00
(-
2.
69
%)
Mankind Pharma
2,438.00
(-
0.
73
%)
Laurus Labs
1,854.00
(+
0.
53
%)
Dr Reddys Laboratories
1,158.80
(-
1.
13
%)
Aurobindo Pharma
1,648.00
(-
0.
60
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO
Cyclical Trend
Events Calendar